RNR1 Antibody

What is RNR1/RRM1 and what is its primary function in cellular biology?

RNR1/RRM1 (Ribonucleoside-diphosphate reductase large subunit) is a critical enzyme that provides the precursors necessary for DNA synthesis. It catalyzes the biosynthesis of deoxyribonucleotides from corresponding ribonucleotides, serving as an essential component in DNA replication and repair processes . The protein is also known as Ribonucleoside-diphosphate reductase subunit M1 or Ribonucleotide reductase large subunit. RNR1's function is conserved across species, playing a fundamental role in maintaining genomic integrity by ensuring balanced deoxyribonucleotide pools during cell division.

How does RNR1 differ from MT-RNR1, and what research applications are specific to each?

While RNR1 refers to the nuclear-encoded ribonucleotide reductase large subunit involved in dNTP synthesis, MT-RNR1 is a mitochondrially encoded gene that has been associated with various pathological conditions. MT-RNR1 polymorphisms, such as G709A, have been linked to hepatocellular carcinoma prognosis and metastasis . MT-RNR1 A1555G mutation has been correlated with hearing loss phenotypes . Research applications for RNR1 typically focus on DNA replication fidelity and cancer therapy resistance, while MT-RNR1 research often centers on mitochondrial dysfunction, cancer progression markers, and genetic predisposition to certain diseases.

What criteria should researchers consider when selecting an RNR1 antibody for specific experimental applications?

When selecting an RNR1 antibody, researchers should consider:

• Application compatibility: Verify the antibody has been validated for your specific application (IHC-P, WB, etc.)

• Species reactivity: Ensure the antibody recognizes RNR1 in your experimental model organism (human, mouse, etc.)

• Clonality: Monoclonal antibodies (like EPR8482) offer high specificity and batch-to-batch consistency for quantitative studies

• Epitope location: Consider whether the antibody targets functionally relevant domains

• Validation data: Review published literature using the antibody and manufacturer's validation data

• Format: Consider whether you need conjugated or unconjugated antibodies depending on your detection system

Researchers should review both manufacturer testing data and independent validation studies before finalizing their selection .

How can researchers validate the specificity of RNR1 antibodies for their experimental systems?

To validate RNR1 antibody specificity:

• Positive and negative controls: Use tissues/cells known to express or lack RNR1

• Knockdown/knockout verification: Compare antibody signal in RNR1-silenced or knockout samples

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to confirm signal specificity

• Multiple antibody comparison: Test different antibodies targeting distinct RNR1 epitopes

• Western blot analysis: Verify single band at the expected molecular weight (approximately 90 kDa for RNR1)

• Cross-reactivity testing: Ensure no signal in samples lacking the target protein

For immunohistochemistry applications, perform heat-mediated antigen retrieval with citrate buffer pH 6 before proceeding with staining protocols to optimize antigen detection .

What are the optimal protocols for using RNR1 antibodies in immunohistochemistry of formalin-fixed paraffin-embedded tissues?

For optimal IHC-P with RNR1 antibodies:

• Tissue preparation:

  • Use 4-5μm sections from formalin-fixed, paraffin-embedded tissues

  • Deparaffinize completely in xylene and rehydrate through graded alcohols

• Antigen retrieval:

  • Perform heat-mediated antigen retrieval using citrate buffer (pH 6.0)

  • Heat at 95-100°C for 20 minutes in a pressure cooker or microwave

• Antibody incubation:

  • Block endogenous peroxidase activity with 3% H₂O₂

  • Apply protein block to reduce non-specific binding

  • Incubate with RNR1 primary antibody (recommended dilution: 1:100-1:500)

  • Incubate overnight at 4°C or 1-2 hours at room temperature

• Detection:

  • Use appropriate detection system (HRP/DAB or fluorescence-based)

  • Counterstain, dehydrate, and mount

• Controls:

  • Include positive control tissues known to express RNR1

  • Include negative controls (primary antibody omitted)

This protocol has been validated for human and mouse samples, with expected membranous and cytoplasmic staining patterns in positive cells .

What are the recommended procedures for optimizing Western blot analysis using RNR1 antibodies?

For optimal Western blot results with RNR1 antibodies:

• Sample preparation:

  • Lyse cells in RIPA buffer with protease inhibitors

  • Quantify protein concentration (BCA or Bradford assay)

  • Denature samples in reducing buffer at 95°C for 5 minutes

• Gel electrophoresis and transfer:

  • Load 20-30μg protein per lane on 8-10% SDS-PAGE gels

  • Transfer to PVDF or nitrocellulose membranes (75-90 minutes at 100V)

• Antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour

  • Incubate with RNR1 primary antibody (1:1000-1:2000 dilution) overnight at 4°C

  • Wash 3x with TBST

  • Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature

• Detection and analysis:

  • Develop using ECL reagent

  • Expected band size for RNR1: ~90 kDa

  • Normalize to appropriate loading controls (β-actin, GAPDH)

• Troubleshooting:

  • For weak signals, increase antibody concentration or protein loading

  • For high background, increase blocking time or washing steps

  • For multiple bands, optimize lysis conditions to prevent protein degradation

This protocol has been validated for detecting endogenous RNR1 in human and mouse samples .

How can RNR1 antibodies be used to investigate the relationship between dNTP pool imbalances and mutator phenotypes in cancer research?

RNR1 antibodies can provide crucial insights into dNTP pool imbalances and resulting mutator phenotypes through:

• Expression correlation studies:

  • Use RNR1 antibodies to quantify protein expression in cancer samples

  • Correlate expression levels with measured dNTP pool imbalances

  • Analyze mutation frequency and spectrum in corresponding samples

• Functional domain analysis:

  • Use epitope-specific antibodies to investigate allosteric regulation domains

  • Examine how mutations affecting specific domains correlate with dNTP imbalances

  • Research from yeast models has shown that mutations in RNR1 can cause severe dNTP imbalances where three out of four dNTPs become elevated (particularly dCTP, dTTP, and dGTP)

• Mechanistic investigations:

  • Combine RNR1 immunoprecipitation with mass spectrometry to identify interacting partners

  • Investigate how dNTP pool imbalances affect DNA polymerase fidelity

  • Research shows RNR1 mutations with the highest dGTP concentrations were most mutagenic

• Therapeutic target identification:

  • Screen for compounds that normalize dNTP pools in RNR1-mutant cells

  • Use RNR1 antibodies to monitor protein levels during treatment

This approach can reveal how specific RNR1 mutations contribute to genomic instability in cancer, as demonstrated in yeast models where RNR1 mutations significantly increased mutation rates through dNTP pool imbalances .

What methodologies can researchers employ to study the association between RNR1 expression and DNA damage response pathways?

To investigate RNR1's role in DNA damage response:

• Co-immunoprecipitation studies:

  • Use RNR1 antibodies to pull down protein complexes

  • Identify interacting partners in DNA damage response pathways

  • Compare interaction profiles before and after DNA damage induction

• ChIP-seq analysis:

  • Perform chromatin immunoprecipitation with RNR1 antibodies

  • Map RNR1 recruitment to specific genomic regions after DNA damage

  • Correlate with DNA repair factor recruitment

• Proximity ligation assays:

  • Visualize in situ interactions between RNR1 and DNA repair proteins

  • Quantify changes in interaction frequency after DNA damage

• Immunofluorescence microscopy:

  • Track RNR1 localization changes after DNA damage

  • Co-stain with γH2AX or 53BP1 to correlate with DNA damage sites

  • Analyze recruitment kinetics in different cell cycle phases

• Flow cytometry:

  • Quantify RNR1 expression levels in response to genotoxic stress

  • Correlate with cell cycle markers and DNA damage indicators

These approaches can elucidate how RNR1 expression and localization changes contribute to maintaining genomic stability after DNA damage, particularly through regulated dNTP production during repair processes.

How can RNR1 antibodies be utilized to study the correlation between RNR1 expression and cancer prognosis or treatment response?

RNR1 antibodies can be valuable tools for investigating cancer prognosis and treatment response:

• Tissue microarray analysis:

  • Perform IHC staining of tumor tissue microarrays with RNR1 antibodies

  • Quantify expression levels and correlate with patient survival data

  • Stratify by cancer subtype, stage, and treatment regimen

• Treatment response prediction:

  • Compare pre- and post-treatment RNR1 expression in patient samples

  • Correlate expression changes with treatment outcomes

  • Develop prediction algorithms incorporating RNR1 expression data

• Combination biomarker panels:

  • Analyze RNR1 expression alongside other established biomarkers

  • Develop multiparameter scoring systems to improve prognostic accuracy

  • Research indicates that expression level of related genes like MT-RNR1 may serve as predictors for chemotherapy response in ovarian cancer

• Liquid biopsy applications:

  • Detect circulating tumor cells expressing RNR1

  • Monitor treatment response through sequential sampling

  • Correlate with disease progression or recurrence

• Therapeutic resistance mechanisms:

  • Investigate RNR1 expression in treatment-resistant vs. sensitive tumors

  • Identify molecular pathways contributing to resistance

  • Develop targeted strategies to overcome resistance

This approach can identify patient subgroups most likely to benefit from specific treatments, similar to how MT-RNR1 G709A polymorphism has been identified as an independent prognostic factor in hepatocellular carcinoma .

What are the methodological considerations when using RNR1 antibodies to investigate mitochondrial dysfunction in disease states?

When investigating mitochondrial dysfunction using RNR1-related antibodies:

• Subcellular fractionation techniques:

  • Optimize protocols to isolate pure mitochondrial fractions

  • Use RNR1 and MT-RNR1 specific antibodies to distinguish between nuclear and mitochondrial forms

  • Verify fraction purity with compartment-specific markers

• Dual immunofluorescence approaches:

  • Co-stain with mitochondrial markers (TOMM20, Mitotracker)

  • Use super-resolution microscopy for precise localization

  • Quantify colocalization coefficients for statistical analysis

• Functional correlation studies:

  • Measure respiratory chain complex activity in samples with varying RNR1/MT-RNR1 levels

  • Correlate antibody staining intensity with functional parameters

  • Research indicates MT-RNR1 polymorphisms like G709A correlate with metabolic changes including hexokinase 2 (HK2) expression in HCC patients

• Mutation-specific antibodies:

  • Develop or select antibodies that can distinguish between wild-type and mutant forms

  • Use to screen patient cohorts for specific variants

  • Apply in tissues known to be affected by mitochondrial dysfunction

• Live-cell imaging:

  • Monitor mitochondrial dynamics in cells with altered RNR1/MT-RNR1 expression

  • Correlate morphological changes with functional outcomes

  • Assess impact of therapeutic interventions

These methodologies can reveal how MT-RNR1 variants contribute to disease pathogenesis, similar to findings that MT-RNR1 G709A is associated with hepatocellular carcinoma progression and metastasis .

What are the most common technical challenges when using RNR1 antibodies in immunohistochemistry, and how can researchers overcome them?

Common challenges with RNR1 antibodies in IHC and their solutions:

• Weak or absent staining:

  • Challenge: Insufficient antigen retrieval or antibody concentration

  • Solution: Optimize heat-mediated antigen retrieval with citrate buffer pH 6.0; increase antibody concentration; extend incubation time

  • Validation: Compare with positive control tissues known to express RNR1

• High background staining:

  • Challenge: Non-specific antibody binding or inadequate blocking

  • Solution: Increase blocking time (5% BSA or 10% normal serum); optimize antibody dilution; increase washing steps

  • Validation: Include secondary-only control to identify source of background

• Variable staining intensity:

  • Challenge: Tissue fixation inconsistencies

  • Solution: Standardize fixation protocols; use pressure cooker for antigen retrieval

  • Validation: Include internal control tissues on each slide

• False negative results:

  • Challenge: Epitope masking or antibody specificity issues

  • Solution: Try multiple antibodies targeting different epitopes; verify RNR1 expression in samples via alternative methods

  • Validation: Perform parallel Western blot analysis

• False positive staining:

  • Challenge: Cross-reactivity with similar proteins

  • Solution: Validate with peptide competition assays; use monoclonal antibodies for higher specificity

  • Validation: Confirm using genetic knockdown models

Implementing these strategies can significantly improve the reliability and reproducibility of RNR1 immunohistochemistry results.

How can researchers accurately interpret and quantify RNR1 protein expression patterns in complex tissue samples?

For accurate interpretation and quantification of RNR1 expression:

• Multi-parameter analysis:

  • Employ digital pathology systems to analyze multiple parameters simultaneously

  • Assess staining intensity, percentage of positive cells, and subcellular localization

  • Correlate with adjacent serial sections stained for related markers

• Standardized scoring systems:

  • Implement H-score (0-300) calculation: % positive cells × intensity (1-3)

  • Use automated image analysis software calibrated with manual scoring

  • Establish cut-off values for "high" vs "low" expression based on clinical outcomes

• Cell type-specific quantification:

  • Use dual immunofluorescence to identify RNR1 expression in specific cell populations

  • Employ tissue segmentation algorithms to analyze tumor vs. stromal compartments

  • Quantify nuclear vs. cytoplasmic staining separately

• Batch effect minimization:

  • Include reference standards in each staining batch

  • Normalize quantification across batches using reference samples

  • Process all comparative samples in the same batch when possible

• Biological validation:

  • Correlate protein expression with mRNA levels from parallel samples

  • Confirm functional significance through mechanistic studies

  • Validate findings across independent patient cohorts

This comprehensive approach allows for robust quantification similar to methodologies used in studies of MT-RNR1 expression in cancer tissues, where expression patterns were correlated with clinical outcomes and molecular mechanisms .

What methodologies can researchers employ to investigate the relationship between RNR1 mutations and dNTP pool imbalances in disease models?

Advanced methodologies for studying RNR1 mutations and dNTP imbalances:

• CRISPR-Cas9 gene editing:

  • Generate precise RNR1 mutations mirroring those found in disease states

  • Create isogenic cell line panels differing only in RNR1 status

  • Research in yeast models has identified 24 different RNR1 mutations causing diverse mutator phenotypes linked to dNTP imbalances

• dNTP pool measurement:

  • Employ HPLC-MS/MS for accurate quantification of all four dNTPs

  • Compare dNTP ratios rather than absolute levels

  • Research has shown that mutations causing elevation in three out of four dNTPs (dCTP, dTTP, and dGTP) are particularly mutagenic

• Fluctuation analysis for mutation rate determination:

  • Use reporter systems like CAN1 inactivation assay for general mutagenesis

  • Employ frameshift reversion assays (hom3-10, lys2-10A) for specific mutation types

  • Compare mutation rates across different RNR1 variant models

• Mutation spectra analysis:

  • Sequence mutated genes to determine the types of mutations caused by dNTP imbalances

  • Analyze mutational hotspots and compare spectra using statistical methods

  • Correlate specific mutation patterns with particular dNTP imbalances

• Structure-function relationship studies:

  • Use crystal structure information to predict how mutations affect allosteric regulation

  • Focus on regions like the flexible loop 2 that interconnects the S-site with the C-site

  • Investigate how specific mutations affect binding of allosteric effectors (ATP, dATP, dTTP, dGTP)

These methodologies can reveal how RNR1 mutations drive genomic instability through dNTP pool imbalances, potentially identifying novel therapeutic targets.

How can researchers design experiments to study the interplay between RNR1 expression and DNA repair pathway efficiency?

Experimental design for investigating RNR1 and DNA repair interactions:

• Synthetic genetic interaction screens:

  • Combine RNR1 mutations with DNA repair gene knockouts

  • Use plasmid shuffling experiments to identify genetic interactions resulting in growth defects or synthetic lethality

  • Research in yeast has demonstrated that RNR1 mutations can exacerbate DNA repair deficiencies like EXO1 deletion

• DNA damage response kinetics:

  • Induce DNA damage in cells with different RNR1 expression levels

  • Monitor repair kinetics using comet assays, γH2AX foci resolution, or reporter constructs

  • Compare repair efficiency across multiple DNA damage types (DSBs, crosslinks, base damage)

• Live-cell imaging of repair foci:

  • Track DNA repair protein recruitment (like Pms1-GFP) in RNR1 mutant backgrounds

  • Quantify focus formation and resolution kinetics

  • Compare different RNR1 variants for their impact on repair timing

• Replication stress analysis:

  • Measure fork progression rates using DNA fiber assays

  • Compare fork stalling and collapse frequencies across RNR1 variants

  • Correlate with dNTP pool measurements

• Pathway-specific repair assays:

  • Design reporter constructs for specific repair pathways (HR, NHEJ, MMR, BER)

  • Quantify pathway efficiency in cells with different RNR1 status

  • Research in yeast has shown that RNR1 mutations can particularly affect mismatch repair efficiency

These experimental approaches can elucidate how RNR1 expression levels and mutations affect specific DNA repair pathways, potentially revealing novel therapeutic vulnerabilities in cancer.

How do research methodologies for studying RNR1 differ between cancer and non-cancer disease models?

Methodological differences in RNR1 research across disease models:

What experimental approaches can researchers use to investigate the role of RNR1 in maintaining genomic stability during cellular stress?

Experimental approaches for studying RNR1 in genomic stability:

• Stress induction models:

  • Expose cells to various stressors (replication inhibitors, oxidative stress, hypoxia)

  • Monitor RNR1 expression changes via Western blot and RT-qPCR

  • Correlate expression with dNTP levels and mutation rates

  • Research in yeast has shown that RNR1 mutations can significantly increase mutation rates under stress conditions

• DNA damage response pathway analysis:

  • Analyze checkpoint activation (ATR/ATM signaling) in RNR1-mutant cells

  • Monitor γH2AX focus formation and resolution kinetics

  • Compare cell cycle progression patterns after stress induction

• Mutagenesis reporter systems:

  • Implement CAN1 inactivation assays for general mutagenesis measurement

  • Use frameshift reporters like hom3-10 and lys2-10A for specific mutation types

  • Compare mutation spectra analysis between wild-type and mutant RNR1

• Genomic instability markers:

  • Analyze chromosome segregation errors via live-cell imaging

  • Quantify micronuclei formation as indicator of genomic instability

  • Measure telomere dysfunction and chromosomal rearrangements

• Synthetic genetic interactions:

  • Combine RNR1 variants with mutations in DNA replication fidelity genes

  • Screen for synthetic growth defects or lethality

  • Research has demonstrated that RNR1 mutations can have synergistic effects with DNA repair deficiencies like EXO1 deletion

These approaches can reveal how RNR1 contributes to genomic stability maintenance under various stress conditions, potentially identifying contexts where RNR1 function becomes particularly critical.